Navigation Links
AvidBiotics Corp. Granted Key U.S. and European Patents on Unique Protein Modification Platform
Date:11/12/2009

SOUTH SAN FRANCSICO, Calif., Nov. 12 /PRNewswire/ -- AvidBiotics Corp. announced the issuance of foundational patents encompassing a completely novel mechanism for generating massive diversity within precisely targeted sites of protein-encoding DNA sequences. The technology platform is referred to as Diversity Generating Retroelements (DGR) and patents were issued in both the United States (#7,585,957) and in Europe (#1,173,995). UCLA and AvidBiotics Corp are co-assignees of the patents, and AvidBiotics holds exclusive, worldwide rights to the patents from UCLA.

"These patents substantiate the novel ground-breaking work of our co-founder, Jeffrey F. Miller, and could lead to an entirely new, more efficient way of creating new protein therapeutics and improving the safety and/or efficacy of existing therapeutic proteins", said David Martin, Jr., chief executive officer of AvidBiotics. "Due to the magnitude of potential diversification and unique functionality, the DGR system as a technology platform could also enable the creation of new diagnostic reagents. At AvidBiotics, we are using this exciting technology to discover and develop novel antibacterials, antivirals and anti-cancer agents."

The advantages of the DGR system over more traditional tools include: 1) the unprecedented size of library diversity; 2) the ease of use; 3) the focused nature of the mutations; and 4) the ability to keep repeating the mutagenic cycles without loss of the protein scaffold or previous gains.

AvidBiotics' focus is to utilize the DGR system to diversify natural R-type pyocins (Avidocin(TM) proteins) to target problematic pathogens affecting human health and the safety of the food supply, for example, Clostridium difficile and E. coli O157:H7, respectively. Additionally, the company is modifying a known mechanism and scaffold using the DGR to target highly virulent viral pathogens of interest to the biodefense community.

About AvidBiotics

AvidBiotics Corp is a biotherapeutics company with a proprietary technology platform focused on the development of genetically modified protein products for the treatment of major infectious diseases, both bacterial and viral. Founded in 2004, by David Martin, Jr., Jeffery F. Miller, and James Knighton, based on technology discovered by Dr. Miller and colleagues, AvidBiotics has technology that enables diversification of protein structures in a precise manner. The core technology has direct applicability to human therapeutics and diagnostics, veterinary medicine, agriculture and food safety, research tools and reagents. AvidBiotics is headquartered in South San Francisco, California. For more information go to www.avidbiotics.com.

SOURCE Avidbiotics Corp.


'/>"/>
SOURCE Avidbiotics Corp.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Michael Troullis Appointed Chief Financial Officer of Quintiles Transnational Corp.
3. ThermoGenesis Corp. to Announce Fourth Quarter and Year End Results for Fiscal Year 2007 on September 12, 2007
4. ThermoGenesis Corp. Reports Fourth Quarter and Fiscal Year 2007 Results
5. MAKO Surgical Corp. Files Registration Statement for Initial Public Offering of Common Stock
6. CellCyte Genetics Corp. Forms Device Division to Develop and Manufacture Stem Cell Cultivation and Replication Products
7. ThermoGenesis Corp. to Present at 2007 Global Life Sciences Conference on Thursday, September 27, 2007
8. Helix BioPharma Corp. announces fiscal 2007 results
9. ThermoGenesis Corp. to Announce First Quarter Fiscal 2008 Results on November 8, 2007
10. Patent on Technology for the Delivery of Stem Cells to the Human Heart Issued to CellCyte Genetics Corp. of Washington
11. Helix BioPharma Corp. announces management changes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... Cancer experts from Austria, ... could be a new and helpful biomarker for malignant pleural mesothelioma. Surviving Mesothelioma ... read it now. , Biomarkers are components in the blood, tissue or ...
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... the funding of a Sponsored Research Agreement with ... tumor cells (CTCs) from cancer patients.  The funding ... CTC levels correlate with clinical outcomes in cancer ... data will then be employed to support the ...
(Date:6/24/2016)... Brooklyn, NY (PRWEB) , ... June 24, 2016 , ... ... 15mm, machines such as the Cary 5000 and the 6000i models are higher end ... height is the height of the spectrophotometer’s light beam from the bottom of the ...
(Date:6/23/2016)... Mass. , June 23, 2016   ... development of novel compounds designed to target cancer ... napabucasin, has been granted Orphan Drug Designation from ... the treatment of gastric cancer, including gastroesophageal junction ... stemness inhibitor designed to inhibit cancer stemness pathways ...
Breaking Biology Technology:
(Date:6/7/2016)... , June 7, 2016  Syngrafii Inc. and ... business relationship that includes integrating Syngrafii,s patented LongPen™ ... project. This collaboration will result in greater convenience ... credit union, while maintaining existing document workflow and ... ...
(Date:6/2/2016)... -- Perimeter Surveillance & Detection Systems, Biometrics ... Support & Other Service  The latest report ... analysis of the global Border Security market . ... $17.98 billion in 2016. Now: In November ... software and hardware technologies for advanced video surveillance. ...
(Date:5/16/2016)...   EyeLock LLC , a market leader of ... an IoT Center of Excellence in Austin, ... of embedded iris biometric applications. EyeLock,s iris ... security with unmatched biometric accuracy, making it the most ... EyeLock,s platform uses video technology to deliver a fast ...
Breaking Biology News(10 mins):